Inclusion Criteria:

          -  Must have ER+ breast cancer

          -  Metastatic disease; protocol does allow for bone-only disease

          -  Must be receiving endocrine therapy

          -  Must have completed at last 2 months of current endocrine therapy prior to
             registration

          -  Must have adequate hematologic, renal and hepatic function

          -  Prior/concurrent radiation therapy is allowed

          -  Prior chemotherapy is allowed, but last dose must have been at least 2 months prior to
             enrollment

          -  May have diabetes, but must not be taking metformin

          -  Must be able to swallow and retain oral medication

          -  Performance status of 0-2

          -  Treated stable brain metastases are allowed, as long as patient does not require
             steroids or anti-seizure medications

          -  Must be informed of the investigational nature of this study and must have the ability
             to sign informed consent.

        Exclusion Criteria:

          -  Known allergy to grapes or grape seed

          -  More than two prior endocrine therapy regimens for the treatment of metastatic ER+
             breast cancer.

          -  Concurrent use of restricted agents outlined in section 4.5.

          -  History of alcohol abuse within 2 years of registration.